THE CancerTYPE ID TEST REPORT IS DESIGNED TO PROVIDE YOU WITH CLARITY AND QUANTITATIVE RESULTS FOR A MAIN TUMOR TYPE, AND WHEN APPLICABLE, TUMOR SUB-TYPES

CancerTYPE ID is a molecular tool that is recommended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high-complexity clinical laboratory testing.

CancerTYPE ID Indications for Use and Limitations
CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high-complexity clinical laboratory testing.

This test was developed and its performance characteristics determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high-complexity clinical laboratory testing.

MOLECULAR CANCER CLASSIFIER

CANNOT BE EXCLUDED:

Adrenal
Adrenocortical carcinoma
Pheochromocytoma
Brain
Breast adenocarcinoma
Cervical adenocarcinoma
Gastroesophageal adenocarcinoma
Gastrointestinal stromal tumor (GIST)
Germ Cell
Nonseminoma
Seminoma
Head & Neck salivary gland carcinoma
Intestinal
Colorectal adenocarcinoma
Small intestine adenocarcinoma
Kidney
Chromophobe renal cell carcinoma
Clear cell renal cell carcinoma
Renal cell carcinoma
Liver
Hepatocellular carcinoma
Pancreaticoduodenal adenocarcinoma
GallBladder adenocarcinoma
Pancreatic adenocarcinoma
Prostate adenocarcinoma
Sarcoma
Malignt fibrous histiocytoma
Perineic neuroendocrine (NEK)
Leiomyosarcoma
Liposarcoma
Dermatofibrosarcoma Protuberans
Sex cord stromal tumor
Skin based carcinoma
Squamous cell carcinoma
Cervix
Head & Neck Skin
Lung
Thymus
Thyroid
Renal cell carcinoma
Melanoma
Medullary carcinoma
Urinary bladder

Probabilities are based on the tumor’s gene expression similarity to the CancerTYPE ID database of over 2,000 tumors.

Rule Outs:

This test was developed and its performance characteristics determined by bioTheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 to perform high-complexity clinical laboratory testing.

© 2014 bioTheranostics, Inc. CancerTYPE ID is a registered trademark of bioTheranostics, Inc.